• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

S and hemostatic agents based on non-study TEG results may have occurred in some patients. The day-to-day coefficient of variation percentage of TEG MA is less than 7 in our laboratory [42].Enzyme-linked immunosorbent assayStatistical analysis was performed using SAS 9.1.3 SP4 (SAS Institute Inc., Cary, NC, US).Simple correlations were investigated by Pearson correlations, with results displayed as Pearson's r, Pearson's r2 (r2) and P values. To investigate the independent association between endothelial activation and damage (syndecan-1, thrombomodulin, protein C, tPA and 1-Bromo-2-fluoro-4-methoxy-5-nitrobenzene1-Bromo-2-fluoro-4-methoxy-5-nitrobenzene title=View Abstract(s)">PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/22901180 univariate and backwards multivariate linear regression analysis were performed, including variables that were either found to correlate with or expected to influence TEG variables: SOFA score (encompasses assessment of the ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2), mean arterial blood pressure (MAP)/vasopressor requirement, bilirubin, platelet count and creatinine), D-dimer, Owren type PT, p-fibrinogen and crystalloid administration (the previous 24 hours before blood sampling). Individual backwards multivariate linear regression models, including only univariate significant variables, were applied for each investigated biomarker (syndecan-1, thrombomodulin and protein C). Results are presented as regression coefficients () with 95 confidence intervals (CI) and t and P values. The association between syndecan-1 quartile and TEG and FF variables were investigated by univariate linear regression analysis, with syndecan-1 quartile as the explanatory variable, with results displayed PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/15139768 as regression coefficients () with 95 CIs and P values. The association between syndecan-1 quartile and 4-Bromo-5-nitro-1H-indazole presence of fibrinolysis (Ly30 > 0 , yes or no) was investigated by the Cochran-Armitage Trend Test, with results displayed as P values. Descriptive data are presented as medians with interquartile ranges (IQR) or as n (proportions). P values <0.05 were considered to be significant.Soluble endothelial-derived biomarkers were measured by commercially available immunoassays in serum/ plasma, sampled pre-intervention (baseline), according to the manufactures recommendations: syndecan-1 (Diaclone SAS, Besancon, France; lower limit of detection (LLD) 4.94 ng/ml) and soluble thrombomodulin (sTM, Nordic Biosite, Copenhagen, Denmark; LLD 0.31 ng/ml), both in serum; protein C (PC, Helena Laboratories, Beaumont, TX, US; relative quantification); tissue-type plasminogen activator (tPA, Americal Diagnostics (ADI), detects single-chain (sc)tissue type plasminogen activator (tPA), two-chain (tc)-tPA and tPA/PAI-1 complexes; LLD 1 ng/ml) and plasminogen activator inhibitor-1 (PAI-1, Assaypro; LLD 0.07 ng/ml), all in citrated plasma. The biomarkers measured were selected to reflect distinct aspects of endothelial activation and damage: glycocalyx damage (syndecan-1 [43]), endothelial cell damage (soluble thrombomodulin (sTM) [44-46]), endothelial cell activation (tPA and PAI-1 [47]) and protein C-induced natural anticoagulation [48].ResultsPatientsThe 184 patients included in the present study were randomized at two different trial sites (n = 140 (76 ) at Rigshospitalet, n = 44 (24 ) at Bispebjerg Hospital). The patients had a median age of 67 years, with 55 being male (Table 1). The majority of patients presented with pulmonary (60 ) or abdominal (30 ) focus of.